Perspective of Cyclin-dependent kinase 9 (CDK9) as a Drug Target

Author(s): Vladimir Krystof, Sonja Baumli, Robert Furst

Journal Name: Current Pharmaceutical Design

Volume 18 , Issue 20 , 2012

Become EABM
Become Reviewer
Call for Editor


Deregulation of cyclin-dependent kinases (CDKs) has been associated with many cancer types and has evoked an interest in chemical inhibitors with possible therapeutic benefit. While most known inhibitors display broad selectivity towards multiple CDKs, recent work highlights CDK9 as the critical target responsible for the anticancer activity of clinically evaluated drugs. In this review, we discuss recent findings provided by structural biologists that may allow further development of highly specific inhibitors of CDK9 towards applications in cancer therapy. We also highlight the role of CDK9 in inflammatory processes and diseases.

Keywords: Cancer, inflammation, kinase, P-TEFb, inhibitor, therapeutics, angiogenesis, cyclin-dependent kinases (CDKs), anticancer activity, chromosome condensation

open access plus

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2012
Published on: 15 May, 2012
Page: [2883 - 2890]
Pages: 8
DOI: 10.2174/138161212800672750

Article Metrics

PDF: 84